A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults.

Trial Profile

A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Asparaginase; Cytarabine; Daunorubicin; Etoposide; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Results (n=942) of a study evaluating whether single nucleotide polymorphisms in ABCB1 gene are predictive of GO response in patients with AML presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results assessing CD33 Single Nucleotide Polymorphism Score as a predictor of response to Gemtuzumab Ozogamicin (n=817) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results assessing outcomes based on CNS disease status in patients from two COG trials (n=AAML0531 and AAML1031; n=2119) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top